ArticleJournal of thoracic disease2025
Prognostic significance of the 9th TNM lung cancer staging system in SCLC.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Narrative review of the staging classification controversy in stage N3 small cell lung cancer: from the perspective of overlapping Veterans Administration Lung Study Group and International Association for the Study of Lung Cancer definitions.Journal of thoracic disease · 2026Review
- A predictive model for immunotherapy in extensive-stage small cell lung cancer based on peripheral blood.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clinical research and decision-making for small cell lung cancer (SCLC) are still based on the dichotomous classification of limited-stage disease or extensive-stage disease. This study aimed to evaluate the prognosis of the 9th edition of the tumor-node-metastasis (TNM) classification for SCLC in a real-world setting. Methods: This retrospective study included SCLC patients diagnosed between January 2014 and December 2021 in our center. Patients who had undergone complete staging evaluation were re-staged according to the 8th and 9th editions of the TNM classification for lung cancer. Kaplan-Meier analysis was conducted to determine overall survival (OS). Univariate and multivariate analyses were performed using the Cox proportional hazards model to assess the prognostic impact of the relevant factors. Results: A total of 1,329 patients were included in the study. All patients underwent clinical staging, while pathological staging was available on 51 patients. After a median follow-up of 39.67 months [95% confidence interval (CI): 36.28-43.06], the median OS was 15.40 months (95% CI: 14.45-16.35). According to the 8th and 9th TNM classification, the median OS, 1-, 2-, and 3-year OS rates showed a progressive decline with advancing stage. The median OS of the N Conclusions: This retrospective analysis confirmed a significant difference in prognosis between the N
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.